MX2023000263A - Compuestos isoquinolina y su uso en el tratamiento del desequilibrio de ahr. - Google Patents

Compuestos isoquinolina y su uso en el tratamiento del desequilibrio de ahr.

Info

Publication number
MX2023000263A
MX2023000263A MX2023000263A MX2023000263A MX2023000263A MX 2023000263 A MX2023000263 A MX 2023000263A MX 2023000263 A MX2023000263 A MX 2023000263A MX 2023000263 A MX2023000263 A MX 2023000263A MX 2023000263 A MX2023000263 A MX 2023000263A
Authority
MX
Mexico
Prior art keywords
ahr
imbalance
treatment
formula
isoquinoline compounds
Prior art date
Application number
MX2023000263A
Other languages
English (en)
Spanish (es)
Inventor
David H Drewry
Channa K Jayawickreme
Carolyn Selenski
Susan H Smith
Ryan Paul Trump
Carrow Wells
Timothy WILLSON
Cunyu Zhang
William Zuercher
Alison Axtman
Original Assignee
Dermavant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermavant Sciences GmbH filed Critical Dermavant Sciences GmbH
Publication of MX2023000263A publication Critical patent/MX2023000263A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18Aralkyl radicals
    • C07D217/20Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
MX2023000263A 2020-07-16 2021-05-27 Compuestos isoquinolina y su uso en el tratamiento del desequilibrio de ahr. MX2023000263A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063052574P 2020-07-16 2020-07-16
US202063052561P 2020-07-16 2020-07-16
PCT/US2021/034599 WO2022015423A1 (en) 2020-07-16 2021-05-27 ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE

Publications (1)

Publication Number Publication Date
MX2023000263A true MX2023000263A (es) 2023-03-29

Family

ID=79293345

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000263A MX2023000263A (es) 2020-07-16 2021-05-27 Compuestos isoquinolina y su uso en el tratamiento del desequilibrio de ahr.

Country Status (10)

Country Link
US (5) US11267788B2 (https=)
EP (1) EP4185566A4 (https=)
JP (1) JP2023533855A (https=)
KR (1) KR20230041021A (https=)
CN (1) CN116157387A (https=)
AU (1) AU2021308209A1 (https=)
CA (1) CA3185793A1 (https=)
IL (1) IL299756A (https=)
MX (1) MX2023000263A (https=)
WO (1) WO2022015423A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023533855A (ja) 2020-07-16 2023-08-04 ダーマヴァント サイエンシーズ ゲーエムベーハー イソキノリン化合物およびそのAhR不均衡の治療への使用
WO2024020170A1 (en) * 2022-07-21 2024-01-25 Allianthera (Suzhou) Biopharmaceutical Co., Ltd. Aryl hydrocarbon receptor agonist prodrugs and methods of use thereof
US20260069585A1 (en) * 2022-08-30 2026-03-12 Dermavant Sciences GmbH ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES
WO2024152993A1 (zh) * 2023-01-17 2024-07-25 上海泽德曼医药科技有限公司 稠环类化合物、其制备方法及其在医药上的应用
CN117447402A (zh) * 2023-10-18 2024-01-26 德明药泰生物技术(深圳)有限公司 芳香烃受体调节剂类化合物及其制备方法和应用
CN117229208B (zh) * 2023-11-13 2024-02-23 上海泽德曼医药科技有限公司 稠环类化合物、其制备方法及其在医药上的应用
WO2026083733A1 (ja) * 2024-10-18 2026-04-23 株式会社ヤクルト本社 試験方法、ゲル状組成物、及び試験装置

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018123A2 (en) 1991-04-10 1992-10-29 Octamer, Inc. A method for inhibition of retroviral replication
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
ATE404539T1 (de) * 1997-10-02 2008-08-15 Eisai R&D Man Co Ltd Kondensierte pyridinderivate
HRP20040102A2 (en) 2001-07-09 2004-10-31 Combinatorx Combinations for the treatment of inflammatory disorders
WO2003053359A2 (en) * 2001-12-19 2003-07-03 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
IL162533A0 (en) * 2001-12-19 2005-11-20 Atherogenics Inc Chalcone derivatives and their use to treat diseases
JPWO2005063222A1 (ja) 2003-12-26 2007-07-19 協和醗酵工業株式会社 Hsp90ファミリー蛋白質阻害剤
WO2006058201A2 (en) 2004-11-23 2006-06-01 Reddy Us Therapeutics, Inc. Heterocyclic and bicyclic compounds, compositions and methods
GB0704718D0 (en) 2007-03-12 2007-04-18 Prendergast Patrick T Compounds and methods for preventing and treating mucositis
EP2014651A1 (en) 2007-07-12 2009-01-14 Exonhit Therapeutics SA Compounds and methods for modulating Rho GTPases
JP5439127B2 (ja) 2009-11-13 2014-03-12 株式会社さいわいメディカル 乾癬又はアトピー性皮膚炎治療剤
WO2011156626A1 (en) 2010-06-09 2011-12-15 Rutgers, The State University Of New Jersey Antimicrobial agents
GB201216017D0 (en) * 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
AU2013361314A1 (en) 2012-12-20 2015-07-02 Aldeyra Therapeutics, Inc. Peri-carbinols
GB201304041D0 (en) 2013-03-06 2013-04-17 Water Jel Europ Llp Treatment and prophylaxis of radiation dermatitis
US10626094B2 (en) 2014-10-14 2020-04-21 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
JP7138654B2 (ja) * 2017-03-29 2022-09-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 金属錯体
US11548867B2 (en) * 2017-07-19 2023-01-10 Idea Ya Biosciences, Inc. Amido compounds as AhR modulators
EP3752512B1 (de) * 2018-02-13 2023-03-01 Merck Patent GmbH Metallkomplexe
TWI828664B (zh) 2018-03-19 2024-01-11 愛爾蘭商Udc愛爾蘭責任有限公司 金屬錯合物
JP2023533855A (ja) 2020-07-16 2023-08-04 ダーマヴァント サイエンシーズ ゲーエムベーハー イソキノリン化合物およびそのAhR不均衡の治療への使用
WO2023020512A1 (zh) * 2021-08-16 2023-02-23 成都奥睿药业有限公司 取代的吡啶类似物、其制备方法及作为ahr调节剂的用途
CN116947799B (zh) * 2023-03-08 2024-05-03 上海泽德曼医药科技有限公司 酚类化合物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
US20240208910A1 (en) 2024-06-27
EP4185566A4 (en) 2024-12-04
KR20230041021A (ko) 2023-03-23
US20250282730A1 (en) 2025-09-11
US11827605B2 (en) 2023-11-28
AU2021308209A8 (en) 2023-04-13
IL299756A (en) 2023-03-01
CN116157387A (zh) 2023-05-23
AU2021308209A1 (en) 2023-02-09
US12252471B2 (en) 2025-03-18
CA3185793A1 (en) 2022-01-20
JP2023533855A (ja) 2023-08-04
WO2022015423A1 (en) 2022-01-20
US20220153703A1 (en) 2022-05-19
US11267788B2 (en) 2022-03-08
US11548853B2 (en) 2023-01-10
EP4185566A1 (en) 2023-05-31
US20230124135A1 (en) 2023-04-20
US20220017468A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
MX2023000263A (es) Compuestos isoquinolina y su uso en el tratamiento del desequilibrio de ahr.
CR20220371A (es) Agonistas heterocíclicos de glp-1
MX2023007192A (es) Inhibidores de prmt5.
CO2024006030A2 (es) Compuestos de quinolina como inhibidores de kras
SA523440916B1 (ar) Prmt5 مشتقات كربوكساميد ثلاثية الحلقة كمثبطات
CL2022000271A1 (es) Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina.
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
MX390535B (es) Compuestos de amino-triazolopiridina y su uso en el trataniento del cancer.
EA202092896A1 (ru) Гетероциклические и гетероарильные соединения для лечения болезни гентингтона
WO2021147236A9 (zh) 取代氨基丙酸酯类化合物在治疗SARS-CoV-2感染中的应用
EA202092320A1 (ru) Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
EA201691404A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов бромодомена
EA201790088A1 (ru) Ингибиторы syk
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
MX2020007392A (es) Compuestos de benzamida.
MX391410B (es) Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos.
EA201592199A1 (ru) Производные бипиразола в качестве ингибиторов jak
EA201690094A1 (ru) Ингибиторы syk
MX386542B (es) Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen.
MX389104B (es) Compuestos de heterociclo tetraciclicos utiles como inhibidores de la integrasa del vih.
MX2022007171A (es) Compuestos cíclicos y métodos de uso de estos.
JOP20220329A1 (ar) مضاد مستقبل crf1 لعلاج فرط تنسج الكظر الخلقي
CL2023000670A1 (es) Compuestos heterocíclicos como inhibidores del bromodominio cbp/ep300